 JPMorgan has downgraded Humanigen Inc NASDAQ:HGEN to Underweight from Neutral and withdrew its price target after the FDA rejected its Emergency Use request for lenzilumab for hospitalized COVID-19 patients. Related Content: See Why Humanigen Stock Is Plunging To 52-Week Low. 